Zhandos Burkitbayev

Dr. Zhandos Burkitbayev


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YSYuliya Semenova
Yuliya Semenova
ZBZhandos Burkitbayev
Zhandos Burkitbayev
NKNurtas Kalibekov
Nurtas Kalibekov
ADAlexandr Digay
Alexandr Digay
BZBakhyt Zhaxybayev
Bakhyt Zhaxybayev
AMAlmira Manatova
Almira Manatova
Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural mesothelioma is a primary malignancy of the pleura and occurs less often than metastatic pleural disease. Pleural malignancies often present with malignant pleural effusion, which typically indicates advanced-stage disease and is associated with poor overall prognosis. Treatment of pleural malignancies includes both palliative and definitive approaches. Palliative interventions primarily aim to relieve symptoms and improve quality of life. Definitive treatments include systemic chemotherapy, targeted therapy, and immunotherapy, depending on the type and molecular profile of the underlying tumor. In mesothelioma, platinum-based chemotherapy in combination with pemetrexed remains the cornerstone of treatment, while the combination of nivolumab and ipilimumab is recommended as first-line therapy for unresectable disease. For metastatic disease, systemic therapy is typically tailored to the primary tumor’s characteristics. Intrapleural administration of chemotherapeutic agents is one of the therapeutic strategies and hyperthermic intrathoracic chemotherapy and pressurized intrathoracic aerosol chemotherapy are the most recent innovations that are under active investigation. This review provides an up-to-date synthesis of systemic chemotherapy strategies for pleural malignancies, their integration with targeted and immune-based therapies, and recent advances in intrapleural chemotherapy modalities. It also explores existing knowledge gaps and outlines directions for future research and potential changes in clinical practice.

YSYuliya Semenova
Yuliya Semenova
ZBZhandos Burkitbayev
Zhandos Burkitbayev
SSSanzhar Shalekenov
Sanzhar Shalekenov
OSOxana Shatkovskaya
Oxana Shatkovskaya
GDGauhar Dunenova
Gauhar Dunenova
LPLyudmila Pivina
Lyudmila Pivina
Breast cancer (BC) is the most common cancer in Kazakhstan, and a population-based breast cancer screening program was introduced in 2008, initially targeting women aged 50–60 years. It was subsequently expanded in 2018 to include women aged 40–70 years. This study evaluates the national BC screening program from its introduction in 2008 onward, focusing on program outputs, outcomes, and associated expenditures. Several administrative datasets and official sources were analyzed, including the legislative acts database, analytical reports on cancer screening programs, and cancer reporting forms. Trends in key indicators were summarized using the average annual percent change (AAPC). From the program’s inception, the absolute number of women screened increased steadily, with an AAPC of 6.23%. In contrast, the proportion of eligible women covered by screening declined over time, particularly following the expansion of the target age groups in 2018. Stage I BC detected through screening accounted for only about 50% of all stage I BC cases diagnosed nationwide, while the contribution of screening to stage II cancers was below 30%. Neither the introduction nor the subsequent expansion of the BC screening program was associated with statistically significant immediate or trend changes in national BC incidence or mortality rates. These findings may inform evidence-based discussions on potential refinements to BC screening policy and practice in Kazakhstan.

11 November 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
AKAltay Kerimkulov
Altay Kerimkulov
TUTalgat Uskenbayev
Talgat Uskenbayev
TSTomiris Sarina
Tomiris Sarina
MMMeiram Mamlin
Meiram Mamlin
SSSanzhar Shalekenov
Sanzhar Shalekenov
AGAbduzhappar Gaipov
Abduzhappar Gaipov
Background: Gastric cancer is a serious health issue both globally and in Kazakhstan. Worldwide, gastric cancer ranks fifth in incidence, with the highest rates reported in East Asia, the Andes of South America, and Eastern Europe, while the lowest rates are reported in North America, Northern Europe, Africa, and Southeast Asia. Over 70% of the cases occur in resource-limited countries. In Kazakhstan, gastric cancer ranks third in morbidity and second in mortality, representing a serious clinical and social problem. Annually, 1600 deaths from malignant gastric neoplasms are registered. Peritoneal metastasis is considered one of the most severe complications of gastric cancer and has long been regarded as its terminal stage. The average life expectancy of patients with peritoneal metastasis is only 3-6 months, reflecting a high mortality rate and the limited efficacy of current treatments. Objective: We hypothesize that the prophylactic use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) may reduce the incidence of peritoneal metastasis. The aim of this study is to evaluate the incidence of peritoneal metastasis following prophylactic PIPAC in patients with gastric cancer. The primary goal of this research is to evaluate whether adding prophylactic PIPAC to standard treatment before neoadjuvant chemotherapy can reduce the incidence of peritoneal metastasis in patients with locally advanced gastric cancer. Methods: This study is a single-center nonrandomized controlled trial with a planned enrollment of 160 patients. All participants will be included in one of the 2 groups: intervention group (PIPAC + perioperative chemotherapy + gastrectomy with D2 lymphadenectomy) or control group (perioperative chemotherapy + gastrectomy with D2 lymphadenectomy). The primary end point is the incidence of peritoneal metastasis, and the secondary end points are overall survival, recurrence-free survival, treatment-related adverse events, and personal satisfaction. Results: As of September 2025, this study is funded and recruiting; 102 participants have already been enrolled. Recruitment is planned to be performed between January 2025 and December 2026. No interim analyses have been performed; primary results are planned for Q1 2027. The manuscript is expected to be published by Q4 2027. Conclusions: Compared to standard chemotherapy, PIPAC has been reported to significantly improve survival rates in patients with peritoneal metastasis of gastric origin. We suggest that the neoadjuvant use of PIPAC may reduce the incidence of peritoneal metastasis and improve long-term survival outcomes. The results of our study will provide key information on the practicality and viability of PIPAC as a prophylactic technique for preventing the progression of gastric cancer. Trial Registration: ClinicalTrials.gov NCT06784765; https://clinicaltrials.gov/study/NCT06784765 International Registered Report Identifier (IRRID): PRR1-10.2196/78053

4 April 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
AСAytbayev Сhokhan
Aytbayev Сhokhan
JSJamilya Saparbay
Jamilya Saparbay
ZAZhumukov Assylmurat
Zhumukov Assylmurat
ASAbylaikhan Sharmenov
Abylaikhan Sharmenov
ZSZhanat Spatayev
Zhanat Spatayev
ZBZhandos Burkitbayev
Zhandos Burkitbayev
Whipple procedure is a most common performed surgery in patients with benign and malignant tumors of pancreas and periampullary region. There is a scarce of data regarding Whipple procedure outcomes in Kazakhstan. The aim of this study was to analyze Whipple procedure outcomes.All Whipple procedures,performed between 2019 and 2023 in National Research Oncology Center, Astana.Data regarding patients were retrieved from electronic records. 97 patients underwent Whipple procedure for malignant tumor. POPF was the most frequent complication after PD. The 1,2,3-year survivals were 83 %,65 % and 48 % respectively. Median survival after Whipple procedure in our study was 20.5 month (95 % CI 18.2-24.0). Surgery remains the only curative treatment method for patients with pancreatic cancer. POPF occurrence was the most common complication and was higher in comparison to other studies. Our findings demonstrate that the modified Blumgart and Dunk anastomosis with duct-to-mucosa suturing significantly reduce the occurrence of postoperative pancreatic fistula. It can be concluded that first 4 year of experience showed comparable learning curve and further improvement in surgical technique and patient selection can decrease morbidity and mortality rate after pancreatoduodenectomy.

15 April 2025 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Open access
PDF file
DTD. Tuleuova
D. Tuleuova
NMN. Moldakhanova
N. Moldakhanova
AYA. Yelekbayev
A. Yelekbayev
GSG.A. Sydykova
G.A. Sydykova
ZBZhandos Burkitbayev
Zhandos Burkitbayev
ATA. Tuleuova
A. Tuleuova
Relevance: Soft tissue sarcomas (STSs) are rare, aggressive malignant neoplasms that arise from mesenchymal tis-sues. They account for no more than 1% of all malignant tumors, can develop at any age, and are more common in mid-dle-aged and older people.The study aimed to obtain a complete epidemiological picture of soft tissue sarcomas in the Republic of Kazakhstan for 11 years, including data analysis for 2023. It considered various parameters such as age, gender, ethnicity, region, and tumor type.Methods: The presented study included all patients registered in the national cancer registry of Kazakhstan from 2013 to 2023, with a diagnosis of STS (ICD-10 code: C49). The number of STS cases is presented as absolute crude rates per 100,000 population. Standardized morbidity and mortality rates were calculated using the World standard.Results: From 2013 to 2023, 4697 cases of STS were reported, with an average increase in incidence of 13%. The STS incidence was 2.4 cases per 100 thousand population. In terms of prevalence among other types of cancer, STSs ranked 19th in incidence and 18th in mortality and were not among the top 10 causes of mortality and morbidity. The incidence rate of STS for both sexes was 2.1 per 100 thousand population; mortality was 0.8 per 100 thousand popula-tion. Morbidity and mortality were higher among men compared to women by 30% and 35%, respectively. Peaks in the incidence of STS were observed in the age groups 55-64 years (23.6% of cases) and 65-74 years (24%). Mortality from STS was observed in the age groups 55-64 years (24.3% of cases) and 65-74 years (17.5%).Conclusion: STSs are varied, and their diagnosis can be difficult in the early stages. The increasing incidence with age, especially in middle-aged people, emphasizes the importance of active prevention and early diagnosis in older peo-ple.

24 September 2025 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Open access
PDF file
ZBZhandos Burkitbayev
Zhandos Burkitbayev
This inaugural editorial introduces the new journal, "Oncology, Nuclear Medicine and Transplantology," launched by the National Research Oncology Center (NROC) in Kazakhstan. It outlines the journal's mission to serve as a pivotal interdisciplinary platform integrating these three rapidly evolving and interconnected fields. The editorial emphasizes the journal's commitment to addressing significant healthcare challenges at the national level in Kazakhstan, stimulating regional collaboration across Central Asia, and contributing to the global scientific discourse. The goal is to foster the exchange of original research, clinical experiences, and innovative practices to ultimately improve patient care and advance medical science in these critical specialties.